1. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (6250)
  2. Journal Article (2609)
  3. Editorial (87)
  4. Review (79)
  5. Guidelines (60)
  6. Correspondence (51)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6326)
  2. Solid Tumor Oncology Division (5470)
  3. Survivorship Research (2011)
  4. Genitourinary Oncology Service (1728)
  5. Surgery (1636)
  6. Epidemiology and Biostatistics (1482)

More Groups

People
  1. Robert Motzer (443)
  2. Howard Scher (332)
  3. Eileen O'Reilly (301)
  4. Leonard Saltz (286)
  5. Dean Bajorin (275)
  6. Mark Kris (251)

More People

Years
  1. 2025 (143)
  2. 2024 (580)
  3. 2023 (606)
  4. 2022 (583)
  5. 2021 (522)
  6. 2020 (548)

More Years

Publications
  1. Journal of Clinical Oncology (8576)
  2. JCO Precision Oncology (160)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Oncology Practice (91)
  6. JCO Clinical Cancer Informatics (51)

More Publications

Publishers
  1. American Society of Clinical Oncology (9143)

Results (9143)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Mak, B.; Tran, B.; Thomas, H.; Pashankar, F. D.; Hansen, A. R.; Feldman, D. R.; Huddart, R. A.; Wheater, M.; Dunwoodie, E.; Mazhar, D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors
    Meeting Abstract

    Gao, X.; Patnaik, A.; Lakhani, N. J.; Call, J. A.; Galsky, M. D.; Garmezy, B.; Wei, A. Z.; Carter, L.; Powles, T.; Siefker-Radtke, A. O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301)
    Meeting Abstract

    Hansen, A. R.; Zhang, A. Y.; Boni, V.; Mantia, C.; Yu, E. Y.; Weickhardt, A. J.; Robert, M.; Gupta, S.; Morales-Barrera, R.; Hoimes, C. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Kiess, A. P.; Nordquist, L.; Gupta, S.; George, D. J.; Messmann, R. A.; Kantoff, P. W.; Nauseef, J. T.; Bander, N. H.; Antonarakis, E. S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    Chen, Y. W.; Liu, L.; Cheng, Y.; Araneta, A.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Runcie, K.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy
    Meeting Abstract

    Tran, B.; Courtney, K. D.; Sokolova, A.; Horvath, L.; Danila, D. C.; Hawley, J. E.; Pook, D. W.; Brown, L. C.; Whang, Y. E.; Buetikofer, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)
    Meeting Abstract

    Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save